Kindred Biosciences found using ticker (KIN) now have 7 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 14 and 9 with a mean TP of 11.32. With the stocks previous close at 3.92 this is indicating there is a potential upside of 188.8%. The 50 day MA is 3.82 and the 200 day MA is 4.17. The company has a market capitalisation of $158m. Company Website: http://www.kindredbio.com
Kindred Biosciences, a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
